The End of the Blockbuster Era: Precision Medicine Reshapes Oncology
Pharmaceutical giants and venture capital firms are pivoting away from the pursuit of universal “blockbuster” cancer drugs as clinical data suggests that the era of one-size-fits-all oncology is drawing to a close. In laboratories across the United States and Europe, researchers are shifting focus toward highly specific, targeted therapies that address individual genetic mutations rather…